Testing effectiveness (Phase 2)Looking for participantsNCT02491099
What this trial is testing
A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma
Who this might be right for
HER2/Neu+ Uterine Serous Carcinoma
Yale University 50